ReviewClinical and experimental medicine2009
Cancer therapy using tumor-associated antigens to reduce side effects.
Review in Clinical and experimental medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.Cancer biology & therapy · 2024Review
- CAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer.iScience · 2023Article
- Nanoformulation of natural products for prevention and therapy of prostate cancer.Cancer letters · 2013Review
- Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors.Clinical and experimental medicine · 2011Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated antigens recently have become very popular in cancer therapy. They can be targeted to reduce side effects of traditional cancer therapy. In this review, ten promising tumor-associated antigens are being discussed in detail. The characteristics of each one are being reviewed in detail. Monoclonal antibodies attached to traditional anticancer agents can target a specific type of cancer cells thereby reducing the amount of traditional anticancer agents reaching normal tissues. This sort of cancer targeting can be a very attractive anticancer therapy because it substantially reduces the amount of side effects normally caused by traditional anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.